Syneos Health (SYNH) acquisition of StudyKIK strengthens the former's ability to provide technology and insight-driven solutions.
Syneos Health (SYNH) recent partnership develops a more patient-centric travel experience, advances diversity and inclusion in clinical research.
- Company planning for three potential New Drug Application (NDA) filings in three years with the first submission expected in Q3 2022 for lead program SB206 in molluscum contagiosum -
Syneos Health (SYNH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Company targeting New Drug Application (NDA) for SB206 in Q3 2022, following recent clinically and statistically significant topline efficacy results from a pivotal Phase 3 B-SIMPLE4 trial in patients...
Strong performance by the Clinical Solutions and Commercial Solutions segments drove Syneos Health's (SYNH) top line.
Syneos Health (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Chief Executive Officer Alistair Macdonald and Chief Financial Officer Jason Meggs...
Syneos Health (SYNH) reported better-than-expected revenues for the second quarter of 2021 on strong segmental performance.
Syneos Health (SYNH) delivered earnings and revenue surprises of 3.19% and 0.71%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
